Cediranib in Glioblastoma
Pp. 176-183 (8)
Elizabeth R. Gerstner, Jorg H. Dietrich, Daphne Wang and Tracy T. Batchelor
Targeting tumor-derived angiogenesis has emerged as a promising new treatment strategy in patients with glioblastoma. Cediranib (Recentin™) is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptors and has demonstrated improved progression-free survival in an uncontrolled phase II study of patients with recurrent glioblastoma. The drug is taken orally, once daily, and has a manageable side effect profile. In addition, it has potent anti-edema and steroid-sparing effects that might improve the quality of life of glioblastoma patients. Several clinical trials are ongoing testing cediranib in patients with gliomas.
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114.